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Lymphatic filariasis is a disease of considerable socioeconomic burden in the tropics. Presently used antifilarial drugs
are able to strongly reduce transmission and will thus ultimately lower the burden of morbidity associated with the
infection, however, a chemotherapeutic principle that directly induces a halt or improvement in the progression of the
morbidity in already infected individuals would constitute a major lead. In search of such a more-effective drug to
complement the existing ones, in an area endemic for bancroftian filariasis in Ghana, 33 microfilaremic and 18
lymphedema patients took part in a double-blind, placebo-controlled trial of a 6-wk regimen of 200 mg/day
doxycycline. Four months after doxycycline treatment, all patients received 150–200 lg/kg ivermectin and 400 mg
albendazole. Patients were monitored for Wolbachia and microfilaria loads, antigenemia, filarial dance sign (FDS),
dilation of supratesticular lymphatic vessels, and plasma levels of lymphangiogenic factors (vascular endothelial
growth factor-C [VEGF-C] and soluble vascular endothelial growth factor receptor-3 [(s)VEGFR-3]). Lymphedema
patients were additionally monitored for stage (grade) of lymphedema and the circumferences of affected legs.
Wolbachia load, microfilaremia, antigenemia, and frequency of FDS were significantly reduced in microfilaremic
patients up to 24 mo in the doxycycline group compared to the placebo group. The mean dilation of supratesticular
lymphatic vessels in doxycycline-treated patients was reduced significantly at 24 mo, whereas there was no
improvement in the placebo group. Preceding clinical improvement, at 12 mo, the mean plasma levels of VEGF-C and
sVEGFR-3 decreased significantly in the doxycycline-treated patients to a level close to that of endemic normal values,
whereas there was no significant reduction in the placebo patients. The extent of disease in lymphedema patients
significantly improved following doxycycline, with the mean stage of lymphedema in the doxycycline-treated patients
being significantly lower compared to placebo patients 12 mo after treatment. The reduction in the stages manifested
as better skin texture, a reduction of deep folds, and fewer deep skin folds. In conclusion, a 6-wk regimen of antifilarial
treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma
levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels
and with an improvement of pathology in lymphatic filariasis patients.
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Introduction
Bancroftian ﬁlariasis is a mosquito-transmitted parasitic
disease of humans characterized by lymphangitis, hydrocele,
lymphedema, and elephantiasis, and is one of the most
common causes of global disability [1]. The disease has been
considered to be potentially eradicable due to the fact that
antiﬁlarial drugs currently used could break the cycle of
transmission in endemic areas. The goals of the current
global lymphatic ﬁlariasis (LF) elimination program are (1) to
reduce microﬁlaremia levels with ﬁlaricidal drugs to a level
that is too low to sustain transmission of ﬁlarial parasites to
humans; and (2) to reduce the morbidity associated with
chronic ﬁlarial disease [2].
The antiﬁlarial drugs currently used, diethylcarbamazine
(DEC) and ivermectin, are predominantly active against
microﬁlariae (MF), with DEC showing partial activity against
adult worms [3]. Mass drug applications using DEC, which acts
on the adult worms that are believed to be major inducers of
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the lymphatic pathology, have been reported to lead to an
improvement of pre-existing lymphedema and hydrocele
[4,5]; similar ﬁndings were observed in a controlled treatment
study using different regimens of DEC [6]. However, these
results are not unequivocal, since several other studies could
not conﬁrm these ﬁndings even when DEC was administered
for 12 d instead of the usual single dose of the mass drug
administration (MDA) [7–12]. This inconsistency was also
acknowledged in a conference by experts of the ‘‘Filariasis
Community of Scientists in Association with an LF Research
Forum’’ convened in Philadelphia, December 2003 [13].
Thus, a drug with stronger macroﬁlaricidal activity than
reported for DEC, which simultaneously has ameliorating
effects on lymphatic vessels, could considerably improve the
prospect of developing a treatment for lymphatic pathology.
One aspect of the biology of ﬁlarial nematodes that could be
exploited in the effort to advance the elimination program is
the presence of the endosymbiotic Wolbachia found in most
ﬁlarial species, including W. bancrofti [14]. Recent studies of
symbiotic Wolbachia organisms suggest that these bacteria are
important both as chemotherapeutic targets and disease-
causing organisms [14]. In a laboratory model of onchocercal
keratitis, Wolbachia was shown to mediate neutrophil inﬁltra-
tion and stromal haze when a worm extract including
Wolbachia antigens was injected into the eyes of mice [15–17].
The events that lead to the development of chronic
pathology in LF are not fully understood, but the immune
responses of the human host to the parasites are believed to
play a signiﬁcant role in determining the pathological
manifestations of disease in infected individuals [18–21].
The lymphatic vascular system is important for immune
surveillance, tissue ﬂuid homeostasis, and fat absorption
[22,23]. Perturbations in the maintenance and function of the
lymphatic systemcan lead toavariety ofpathological disorders,
including lymphatic dilation and lymphedema [24–26].
Recent studies on the molecular mechanisms controlling
the lymphatic vessels have shown that vascular endothelial
growth factors C (VEGF-C) and VEGF-D speciﬁcally control
lymphangiogenesis in humans [27,28] by activating the VEGF
receptor-3 (VEGFR-3) [29–32], which is principally restricted
to the lymphatic endothelium in adults [33,34]. In animal
models, overexpression of VEGF-C in the skin of transgenic
mice resulted in lymphatic endothelial proliferation and
dilation of lymph vessels [32] with a resemblance to
lymphatics infected with ﬁlarial parasites [35]. Additional
evidence for the role of VEGF-C/VEGF-D/VEGFR-3 in the
pathogenesis of lymphatic dilation and lymphedema stems
from experimental studies in transgenic mice with skin
speciﬁc overexpression of soluble VEGFR-3 (sVEGFR-3)
using a keratin 14 transgenic promoter [36]. In this genetic
model, sVEGFR-3 is secreted at high levels by basal
epidermal keratinocytes and binds the lymphangiogenesis
factors VEGF-C and VEGF-D, thereby preventing them from
activating membrane-bound VEGFR-3 on lymphatic endo-
thelium [36]. These K14/ sVEGFR-3 transgenic mice lack a
functional cutaneous lymphatic system and are character-
ized by lymphedema formation in the skin. The expression
of VEGF-C has been shown to be up-regulated by proin-
ﬂammatory cytokines like interleukin (IL)-1B and tumor
necrosis factor (TNF), suggesting that proinﬂammatory
cytokines could affect the lymphatic vessels via VEGF-C [37].
Studies in animal models have shown that Wolbachia–
derived molecules from Brugia spp. induced proinﬂammatory
cytokines, including TNF and IL-1B [38]. Soluble extracts of
Brugia and Onchocerca volvulus adult and microﬁlarial worms
were also found to stimulate human peripheral mononuclear
cells in vitro, resulting in the production of TNF, IL-1,
granulocyte-macrophage colony-stimulating factor (GM-
CSF), and IL-10 [39,40]. This stimulation was not achieved
using extracts from Acanthocheilonema viteae, a ﬁlarial species
naturally devoid of Wolbachia, and, importantly, with O.
volvulus extracts from patients that had been treated with
doxycycline to deplete Wolbachia from the worms [41]. Thus it
was concluded that in those ﬁlarial species that contain these
endosymbionts, Wolbachia are the major stimulating principle
for proinﬂammatory cytokines such as TNF. From this it can
be further hypothesized that exposure of host cells to
Wolbachia from worms (either from dying adult worms or
incoming L3/4 larvae, or from the proportion of degenerating
embryos that are constantly released) may induce the
production of lymphangiogenic factors such as VEGF-C by
endothelial cells in LF patients.
Treatment with doxycycline for 8 wk is well tolerated in
humans and has shown macroﬁlaricidal activity [42]. Doxycy-
cline is also effective in depletingWolbachia from both MF and
adult ﬁlarial worms of W. bancrofti and O. volvulus [43,44]. Of
importance for the present study, Wolbachia depletion by
doxycycline was associated with a reduction of pretreatment
elevated levels of proinﬂammatory cytokines such as TNF
from plasma [45]. Together, these data allow the hypothesis
that targeting Wolbachia by doxycycline may ameliorate
ﬁlarial pathology through down-regulation of proinﬂamma-
tory cytokines and VEGF-C/VEGFR-3. However, no studies to
date have analyzed Wolbachia-induced secretion of VEGF-C
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Synopsis
Lymphatic filariasis, caused by filarial worms, is transmitted by
mosquitoes. The infection leads to pathology such as edema of the
legs (lymphedema) or the scrotum (hydrocele). About 120 million
people are estimated to be infected, and 1.2 billion are at risk of
infection. The currently used drugs (diethylcarbamazine [DEC] or
ivermectin plus albendazole) to treat the disease are able to kill most
of the larval stage (microfilariae) in the blood but have either no
(ivermectin) or partial (DEC) effect on the adult worms that cause
the pathology. They also do not sufficiently halt the progression of
pathology, such as, lymph vessel dilation, hydrocele, and lymphe-
dema.
In search of a more effective drug capable of killing the adult worms,
and also of halting the progression of the disease in already infected
individuals, the authors recruited, in an endemic area in Ghana, 33
people who were infected with the worm and microfilaremic but
had not yet developed the disease, as well as 18 lymphedema
patients, and treated them with either 200 mg/d doxycycline or
matching placebo for 6 wk. The findings presented here reveal that
doxycycline is able to kill the adult worms, improves lymphatic
vessel dilation, and ameliorates the conditions of lymphedema
patients significantly. This suggests that doxycycline can be used to
treat lymphatic filarial infections and pathology, making doxycycline
the first drug already approved for human use and considered for
use as an adjunct to current control programs, which in addition to
parasite control achieves improvement of the quality of life of
persons with pathology.
and its receptor on lymphatic vessel dilation among human
populations with lymphatic ﬁlarial disease.
The aims of this study were to assess (1) a 6-wk course of
doxycycline for macroﬁlaricidal activity; (2) the effect of
targeting the endosymbioticWolbachia in ﬁlarial worms on the
levels of VEGF-C and its soluble receptor VEGFR-3 and on
dilation of the supratesticular lymphatic vessels in micro-
ﬁlaremic patients; and (3) the effect of doxycycline treatment
on clinical manifestations associated with ﬁlarial lymphede-
ma. To address these aims, we recruited microﬁlaremic and
lymphedema patients in an endemic area in Ghana and
treated them with 200 mg/d doxycycline for 6 wk. Lymphe-
dema patients were followed up at 4 and 12 mo, whereas
microﬁlaremic patients were re-examined at 4, 12, and 24 mo
after the start of doxycycline treatment. We report that 6 wk
of doxycycline had a strong macroﬁlaricidal activity; and
targeting the endosymbiotic Wolbachia in ﬁlarial worms
resulted in the reduction of plasma levels of VEGF-C/
sVEGFR-3, which were associated with amelioration of
dilated supratesticular lymphatic vessels and improvement
of lymphedema in lymphatic ﬁlariasis patients.
Results
We treated a total 95 patients with bancroftian ﬁlariasis (76
microﬁlaremic and 19 lymphedema) with doxycycline or
matching placebo for 6 wk. The treatment was well tolerated,
with eight doxycycline and ten placebo patients experiencing
adverse reactions, which in no case required a treatment stop.
The adverse reactions arose on days 2 and 3 after commence-
ment of treatment in both groups. The adverse reactions
experiencedby theeightdoxycycline-treatedpatients included
headache, dizziness, diarrhea, and itching skin. No adverse
event went beyond 3 d or required more intervention than
application of paracetamol tablets, oral dehydration salt, and
ointment. The adverse reactions experienced by the ten
placebo patients included headache, diarrhea, and painful
scrotum.Againnoevent lasted formore than3d, except forone
microﬁlaremic patient who had a painful scrotum for 6 d. In
this group, the side effects were also treated with paracetamol
tablets and oral dehydration salt. There was no signiﬁcant
difference between the doxycycline and placebo groups.
Thirty-three (17 doxycycline and 16 placebo) microﬁlare-
mic patients and eighteen lymphedema patients (8 doxycy-
cline and 10 placebo) were present at all time points (Table 1),
and the analyses are based on these patients. In all the
analyses, only participants present at all time points were
included. Nonetheless, the signiﬁcant differences observed
were not affected when all patients (including the dropouts at
the follow-up time points as shown in Figure 1A and 1B) were
included in the analyses (unpublished data).
Primary Outcome Analysis in Microfilaremic Patients
Table 1 shows the changes in Wolbachia level, micro-
ﬁlaremia, and antigenemia from baseline and at follow-up
Table 1. Primary Variables Measured before and after Treatment in Microfilaremic Patients
Treatment Group Time Point after Treatment
Before Treatment 4 mo 12 mo 24 mo
Doxycycline GM of Wolbachia load/MF
(10th–90th percentile)
89 (67–184) 4 (0.8–10) 16 (1 patient) 33 (14–69)
p-Valuea p ¼ 0.0418 p , 0.0001 p ¼ 0.1266 p ¼ 0.0330
GM of microfilaremia
(10th–90th percentile)
734 (218–3,650) 550 (88–4,682) 0.10 (0–0) 1.3 (0–111)
p-Valuea p ¼ 0.0293 p ¼ 0.4749 p ¼ 0.0029 p ¼ 0.0211
Number of MF-positive individuals (%) 17/17 (100%) 15/17 (88%) 1/17 (6%) 3/17 (18%)
p-Valuea p . 0.9999 p ¼ 0.6562 p ¼ 0.0066 p ¼ 0.0134
Median of antigenemia in units (%)
(10th–90th percentile)
724,844 (100%)
(74,512–9,596,258)
— 137,265 (19%)
(13,318–1,468,456)
43,622 (6%)
(2,965–163,273)
p-Valuea p ¼ 0.5718 p ¼ 0.1748 p ¼ 0.0382
Number of FDS-positive individuals (%) 11/17 (65%) — 3/17 (18%) 1/17 (6%)
p-Valueb p ¼ 0.4384 p ¼ 0.0004 p ¼ 0.0002
Number of only male
FDS-positive individuals (%)
9/13 (69%) — 3/13 (23%) 1/13 (8%)
p-Valueb 0.3271 0.0013 0.0022
Placebo GM of Wolbachia load/MF
(10th–90th percentile)
66 (30–135) 127 (73–206) 113 (33–327) 91 (43–680)
GM of microfilaremia
(10th–90th percentile)
319 (73–2,109) 590 (169–3,884) 8 (0–359) 22(0–1,700)
Number of MF-positive individuals (%) 16/16 (100%) 13/16 (81%) 8/16 (50%) 10/16 (63%)
Median of antigenemia in units (%)
(10th–90th percentile)
452,085 (100%)
(40,807–6,384,750)
— 313,605 (69%)
(20,607–1,906,708)
236,055 (52%)
(12,455–2,634,917)
Number of FDS-positive individuals (%) 13/16 (81%) — 13/16 (81%) 11/16 (69%)
Number of only male
FDS-positive individuals (%)
10/11 (91%) — 10/11 (91%) 8/11 (73%)
Only 33 patients (17 doxycycline and 16 placebo) present at all time points were included in the analyses.
aChanges in Geometric mean (GM) of Wolbachia load per microfilaria, microfilaremia, and antigenemia values from doxycycline group were compared to those from placebo group and
assessed by Mann-Whitney U tests of raw data.
bChanges in the number of MF-positive individuals and filarial dance sign (FDS)-positive individuals from doxycycline group were compared to those from placebo and assessed using
Fisher’ exact tests.
DOI: 10.1371/journal.ppat.0020092.t001
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time points. In all the analyses, only participants present at all
time points (17 doxycycline and 16 placebo) were included.
Following doxycycline treatment, Wolbachia levels in MF were
reduced by 95% (p , 0.0001) in the doxycycline group, but
there was no signiﬁcant change in the placebo group (p ¼
0.2588).
Microﬁlaremia was only slightly, though not signiﬁcantly,
reduced 4 mo after doxycycline treatment compared to
pretreatment levels in the doxycycline group (p ¼ 0.2741)
whereas microﬁlaria levels had actually increased in the
placebo group (p ¼ 0.0017). Both doxycycline and placebo
patients were given albendazole and ivermectin after the 4
mo re-examination to clear microﬁlaremia. At 12 mo post
therapy, microﬁlaremia was virtually absent in the doxycy-
cline group except in one of the 17 (6%) patients, who had a
very low MF count. At 24-mo follow-up, 18% of doxycycline-
treated patients that were re-examined had microﬁlaremia.
In contrast, 50% of placebo patients became microﬁlaremic
at 12 mo, and the number increased to 63% at 24 mo. The
reduction of MF in the doxycycline group compared to
placebo group was signiﬁcant at the 12 mo (p¼0.0029) and 24
mo (p¼ 0.0211) follow-up time points. It must be mentioned
that all patients continued to live in the endemic area; given a
5-y average life-span of adult worms and constant worm loads
without treatment interference, new infections are expected
to occur at a rate of about 20% per year.
Measurement of Adult Worm Vitality in Microfilaremic
Patients
Circulating ﬁlarial antigen (CFA) levels in plasma, and
presence or absence of worm nests in ultrasound examina-
tions, were used to assess macroﬁlaricidal activity of
doxycycline. CFA did not differ signiﬁcantly between the
two groups before and at 12 mo after treatment (p ¼ 0.5718
and p¼ 0.1748, respectively). However, the difference became
signiﬁcant at 24 mo post therapy (p ¼ 0.0382), with median
CFA levels in the doxycycline group being only 6% of
pretreatment (Table 1). Before doxycycline treatment, all the
33 (17 doxycycline and 16 placebo) patients had antigenemia
levels higher than 32,000 units (highest titer ranking accord-
ing to the manufacturer, TropBio). However, 5/17 (29%) and
11/17 (65%) doxycycline-treated patients had antigen units
lower than the 32,000 units at 12 and 24 mo, respectively,
after treatment, whereas only 3/16 (19%) and 4/16 (25%) of
placebo patients had antigens lower than 32,000 units at these
time points. Ultrasonography to detect the ﬁlarial dance sign
(FDS) as a second parameter of adult worm vitality was
performed only in male patients since our earlier data [46]
had shown that the FDS is detected less frequently and
probably less reliably in women. FDS in the scrotal region
before treatment showed that nine of 13 male patients
examined in the doxycycline group had between 1–4 worm
nests, whereas ten of 11 male patients in the placebo group
had worm nests ranging from 1–5 worm nests. Considering
only those male patients who had detectable FDS before
treatment (nine doxycycline and ten placebo), 67% (6/9) and
Figure 1. Flowchart of Patient Participation
(A) Trial profile of microfilaremic patients. Of the 76 patients, 33 (17
doxycycline and 16 placebo) patients were present at all time points.
(B) Trial profile of lymphedema patients. Of the 19 patients, 18 (eight
doxycycline and ten placebo) patients were present at all time points.
DOI: 10.1371/journal.ppat.0020092.g001
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89% (8/9) of male doxycycline-treated patients became FDS-
negative at 12 and 24 mo after treatment, respectively. In
contrast, all ten male placebo patients remained FDS-positive
at 12 mo and 20% (2/10) were FDS-negative at 24 mo post
therapy. There was no difference between the two groups
before treatment (p¼0.3271); however, the difference became
signiﬁcant at 12 and 24 mo after doxycycline treatment (p ,
0.001, Table 1).
Secondary Outcome Variables in Microfilaremic Patients
Dilation of supratesticular lymphatic vessels. Before dox-
ycycline treatment, ultrasonography (USG) showed that 17
male patients (nine doxycycline and eight placebo-treated)
had supratesticular lymphatic vessel dilation. Figure 2 and
Table 2 illustrate changes, after doxycycline treatment, in the
dilation of lymph vessels that had not contained worms at
study onset. Dilated lymphatic vessels containing no worms
were reduced signiﬁcantly at 24 mo after treatment (p ¼
0.0404) in the doxycycline group but not in the placebo group
(p ¼ 0.2168). Of the nine doxycycline-treated patients, seven
(78%) patients showed a reduction of the lymphatic vessels in
comparison to 1/8 (13%) patients in the placebo group (p ¼
0.0319, Table 2). In addition, lymphatic vessels that had
contained adult worms at study onset were also reduced to
normal in the doxycycline group at 24 mo.
Incidence of hydrocele during the 24-mo observation
period. In support of the hypothesis that doxycycline can
ameliorate lymphatic vessel alteration, more patients in the
placebo group developed a hydrocele during the observation
period compared to the doxycycline group. Thus, one patient
in the doxycycline-treated group developed a clinical hydro-
cele whereas in another patient, the hydrocele disappeared.
In contrast, in the placebo-treated group, ﬁve patients
developed hydrocele (three subclinical, as assessed by USG,
and two clinical). This increase of hydrocele in the placebo
group was signiﬁcant when compared to the pretreatment
status (hydrocele positive/negative at pretreatment: 1/10; at 24
mo: 6/5, p ¼ 0.0221, chi-square test).
Lymphangiogenic factors. Mean plasma concentrations of
VEGF-C and soluble VEGFR-3 (sVEGFR-3) were signiﬁcantly
elevated in microﬁlaremic patients (p , 0.0001, Figure 3, and
p ¼ 0.0006, Figure 4, respectively) compared to endemic
controls, i.e., residents of the same endemic area with no
evidence of infection despite exposure to infective larvae (see
also Materials and Methods). Following doxycycline treat-
ment, mean values of VEGF-C in the doxycycline group were
signiﬁcantly reduced (p¼ 0.0198, Figure 5), whereas there was
no signiﬁcant reduction in the placebo group. Mean plasma
values of sVEGFR-3 in the doxycycline group were also
signiﬁcantly reduced 12 mo after doxycycline treatment to a
level close to that of the endemic normals (p¼ 0.0125, Figure
6). In contrast, mean levels remained almost the same in the
placebo patients. Samples from 24 mo post therapy were not
sufﬁcient in volume for VEGF-C and sVEGFR-3 analysis
because most patients refused to donate the usual 10 ml of
venous blood.
Associations between plasma levels of growth factors and
parasitological parameters. Using pretreatment samples, we
found a positive correlation between VEGF-C and sVEGFR-3
(r ¼ 0.430, p ¼ 0.0014). No correlation was found between
VEGF-C and lymphatic dilation, but a strong trend (r¼ 0.390,
p ¼ 0.0514) was noticed between sVEGFR-3 and lymphatic
vessel dilation. There was also a positive association between
levels of VEGF-C and antigenemia (r¼ 0.434, p , 0.0001) and
between levels of sVEGFR-3 and antigenemia (r ¼ 0.367, p ¼
0.0065), but no associations between microﬁlaremia and
levels of VEGF-C (p¼ 0.8864) and sVEGFR-3 (p¼ 0.7720) were
found.
Primary Outcome Analysis in Lymphedema Patients
CFA and antiﬁlarial antibody titers of lymphedema
patients. Twenty-six lymphedema patients were recruited
Figure 2. The Effect of Doxycycline Treatment on the Supratesticular
Lymphatic Vessel Dilation at Various Time Points
The supratesticular lymphatic vessel dilation (mean of category 6 SD)
was determined before treatment, and 12 and 24 mo thereafter, using
USG. The mean supratesticular lymphatic vessel dilation of doxycycline-
treated (Doxy) patients improved significantly compared to pretreatment
(n ¼ 9, p ¼ 0.0404) at 24 mo, in contrast to the placebo group (n ¼ 8)
(paired t-test).
DOI: 10.1371/journal.ppat.0020092.g002
Table 2. State of Lymphatic Vessel Dilation of Patients before and 24 Months after Doxycycline Treatment
Treatment
Group
Number of Patients
Present before
and at 24 months
Number of Patients
with Improved Condition
Number of Patients
with Same Condition
Number of Patients
with Worsened Condition
p-Valuea
Doxycycline 9 7/9 78% 1/9 11% 1/9 11% 0.0319
Placebo 8 1/8 13% 4/8 50% 3/8 37%
Dilation of the supratesticular lymphatic vessels was determined by measuring largest diameter using the two-dimensional b-mode.
aChanges in the state of lymphatic vessels shows significant difference between doxycycline and placebo patients; p¼ 0.0319 at 24 mo after treatment using the Fisher’ exact test.
DOI: 10.1371/journal.ppat.0020092.t002
PLoS Pathogens | www.plospathogens.org September 2006 | Volume 2 | Issue 9 | e920833
Doxycycline Improves Pathology in LF
(Figure 1B), and 19 met the inclusion criteria. Of the 19
patients, one patient was absent at 12 mo, leaving 18 patients
who were present before and 12 mo after treatment. Of the
18 patients, eight received doxycycline and ten received
placebo (Figure 1B). All lymphedema patients were CFA-
positive except two (one doxycycline- and one placebo-
treated) patients who had CFA levels below the cut-off of 128
units/ml; these two patients however had positive ﬁlarial
antibody titers (all subclasses are measured in this test). One
placebo patient was microﬁlaremic. All 18 patients had
ﬁlarial antibody titers (1:40–1:640).
There were reductions in the antigenemia levels in both
doxycycline and placebo patients with lymphedema at 12 mo,
but no signiﬁcant difference in the reduction was obtained in
any of the groups (Table 3) at this time point. The antibody
levels were signiﬁcantly reduced in the doxycycline-treated
group compared to pretreatment (p¼ 0.0431, Wilcoxon rank
test), whereas there was no signiﬁcant difference in the
placebo-treated group (p ¼ 0.0935, Wilcoxon rank test).
Stages of lymphedema. Table 3 shows the changes in the
lymphedema stage—determined according to the staging
scheme by Dreyer et al. [47]—of the affected legs and the
circumference of the affected legs from baseline and 12 mo
after treatment. The affected legs of all the doxycycline-
treated patients reverted to a lower lymphedema stage at 12
mo post therapy, whereas all the placebo-treated patients
stayed the same or changed to a higher stage at this time
point. There was a signiﬁcant reduction (p¼0.0051, Wilcoxon
rank test) in the lymphedema stage of the doxycycline-treated
patients at 12 mo post therapy compared to pretreatment,
but not in the placebo group). The reduction in the stage
manifested as better skin integrity (fewer ‘‘knobs’’), reduction
of deep and shallow skin folds, and fewer entry lesions of the
affected legs (not shown). No change in the mean circum-
ference of the affected legs in both doxycycline and placebo
groups at 12 mo post therapy was observed.
Lymphangiogenic factors of lymphedema patients. Mean
plasma concentrations of VEGF-C and sVEGFR-3 (Figures 3
and 4) were signiﬁcantly elevated in lymphedema patients (p
¼ 0.0002, and p ¼ 0.0012, respectively) compared to endemic
controls. Interestingly, the plasma levels of sVEGFR-3 were
signiﬁcantly higher in lymphedema patients than in micro-
ﬁlaremic patients without lymphedema (p¼ 0.0024, Figure 4).
Twelve months following doxycycline treatment, mean values
of VEGF-C and sVEGFR-3 in the doxycycline group were
signiﬁcantly reduced (p ¼ 0.0499, Figure 7, and p ¼ 0.0251,
Figure 8, respectively), whereas there were no signiﬁcant
alterations in the placebo group. Since the pretreatment
standard deviation of the sVEGFR-3 levels in the doxycycline
group was rather large, due to one very high value, we also
applied the Wilcoxon test in this case; there was still a
signiﬁcant difference (p¼ 0.0284) in sVEGFR-3 levels between
pretreatment and 12 mo.
Discussion
The past decade has seen major advances that have
changed LF from a neglected disease into a disease now
accepted as potentially eradicable. The main reason is the
identiﬁcation of ivermectin, DEC, and albendazole, as
effective antiﬁlarial agents.
While DEC has been shown to have some macroﬁlaricidal
effect, it is still believed that a more potent macroﬁlaricide
will add to efforts to achieve LF elimination, halting also the
progression of the clinical manifestations induced largely by
the adult worm [48]. This particularly is the case for Africa,
where the use of DEC is discouraged in areas co-endemic for
onchocerciasis, due to the irreversible ocular damage that
DEC induces, different from ivermectin [49,50].
Two major advances have been observed in this study.
Firstly, a regimen of 6 wk of doxycycline against W. bancrofti,
shorter than what we published earlier [42], depleted
Wolbachia endosymbionts and showed a strong macroﬁlarici-
Figure 4. Pretreatment Plasma Levels of sVEGFR-3 in Filaria-Infected
Patients and Endemic Controls
Plasma concentrations (mean 6 SD) of sVEGFR-3 were measured using a
commercial kit from plasma of lymphedema patients (n ¼ 26), micro-
filaremic patients (n ¼ 76), and endemic controls (n ¼ 23, who did not
have filarial infection). Mean plasma levels of sVEGFR-3 were significantly
elevated in the microfilaremic (p¼ 0.0006) and lymphedema patients (p
¼ 0.0012) compared to endemic controls (Student t-test with Bonferroni/
Dunn correction). sVEGFR-3 was also significantly elevated in lymphe-
dema patients (p¼ 0.0024) compared to microfilaremic patients.
DOI: 10.1371/journal.ppat.0020092.g004
Figure 3. Pretreatment Plasma Levels of VEGF-C in Filarial-Infected
Patients and Endemic Controls
Plasma concentrations (mean 6 SD) of VEGF-C were measured, using a
commercial kit, from plasma of lymphedema patients (n ¼ 26),
microfilaremic patients (n ¼ 76), and endemic controls (n ¼ 23, who
did not have filarial infection). Mean plasma levels of VEGF-C were
significantly elevated in the microfilaremic (p , 0.0001) and lymphede-
ma patients (p ¼ 0.0002) compared to endemic controls (Student t-test
with Bonferroni/Dunn correction). There was no difference between
microfilaremic and lymphedema patients (p¼ 0.8033).
DOI: 10.1371/journal.ppat.0020092.g003
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dal activity, as evidenced by reduction of antigenemia by 94%
and the absence of adult worms from the scrotal region in
89% of male participants by USG 24 mo after treatment. The
second and fully novel advance is the reduction of lymphan-
giogenetic factors following doxycycline, and the reduction of
lymphatic vessel dilation and improvement of lymphedema.
Wolbachia Load
We recorded a 95% reduction of Wolbachia load in
doxycycline-treated patients 4 mo after treatment, and this
reduction was sustained throughout the 24-mo follow-up
period. The fact that there was an apparent, but not
signiﬁcant, increase in Wolbachia loads in three MF-positive
doxycycline patients at 24 mo is probably due to new
infections, which is likely to occur in this area of ongoing
transmission, theoretically at a yearly rate of 20% of the total
worm load, given that the average worm life span is about 5 y
and that there is a rather stable adult worm load in adult
patients. New infections with concurrent rise in Wolbachia
levels following doxycycline treatment have already been
documented for doxycycline treatment of onchocerciasis,
where old, doxycycline-treated and thus Wolbachia depleted,
female worms were located in onchocercomas next to young,
nulliparous worms that were full with Wolbachia [51]. Due to
the unavailability of adult worms for histological and PCR
analysis in LF, we could not formally conﬁrm these ﬁndings
for LF. Doxycycline treatment also resulted in almost
complete elimination of microﬁlaremia which was sustained
throughout the 24-mo period. This is consistent with our
previous study [44]. The loss of microﬁlaremia in doxycycline
patients is most likely due to the effect of Wolbachia depletion
on embryogenesis and loss of microﬁlariae from host blood
through natural attrition, as recorded in onchocerciasis
[52,53] and lymphatic ﬁlariasis [42,44].
Antigenemia
Even though antigenemia levels were signiﬁcantly reduced
by 94% in doxycycline-treated microﬁlaremic as compared to
48% in placebo patients, antigen units remained elevated at
24 mo in some doxycycline patients, though USG results
showed the absence of worm nests. Before doxycycline
treatment, all 33 (17 doxycycline and 16 placebo) patients
had antigenemia levels above 32,000 units (the highest level
that can be semiquantitatively determined according to the
manufacturer, TropBio). However, at 24 mo, 11/17 (65%) of
doxycycline-treated patients had antigen units below 32,000,
compared to only 4/16 (25%) of placebo patients. Given that
USG demonstrated absence of worm nests in most doxycy-
cline-treated patients analyzed, our data suggest that anti-
genemia is cleared from the blood slowly, but progressively,
after the death of the adult worms, as suggested by others [54].
The lower proportion of patients with high antigenemia in
the doxycycline group underscores this and shows that it
probably takes more than 24 mo for the antigens to be
cleared from the blood after the death of the adult worms.
We cannot exclude that the partial reduction in anti-
genemia observed in the placebo patients could be due, to
some extent, to a partial macroﬁlaricidal effect of ivermectin
plus albendazole treatment. USG results did show 20% loss of
worm nests at 24 mo; however, this reduction did not reach
statistical signiﬁcance. The lack of signiﬁcance could be due
to the rather small number of placebo patients (n ¼ 16);
however, even if a signiﬁcant difference had been detected
with higher numbers, the extent of the reduction would not
have increased. Thus, our ﬁndings rather support other
reports that ivermectin plus albendazole has no signiﬁcant
macroﬁlaricidal effect [55–57]. Another explanation that
probably accounts for more of the reduction of antigenemia
in the placebo group is the depletion of microﬁlaremia as a
result of the antiﬁlarial treatment offered to all the patients
at the 4-mo time point. In this study, we found a positive
correlation between microﬁlaremia and antigenemia (r ¼
0.754, p , 0.0001). This is consistent with another study [58]
in which a positive correlation between microﬁlaremia and
antigenemia was also reported, implying that as MF in the
blood are depleted, the level of antigenemia also goes down,
hence the reduction seen at 12 and 24 mo after treatment in
Figure 6. Plasma Levels of sVEGFR-3 of Microfilaremic Patients before
and 12 Mo after Doxycycline Treatment
Plasma concentrations (mean 6 SD) of sVEGFR-3 were measured from
plasma of microfilaremic patients before and 12 mo after doxycycline
treatment (17 doxycycline treated, 16 placebo, see Table 1). The sVEGFR-
3 levels decreased significantly at 12 mo (preceding supratesticular
lymphatic dilation, see Table 2) in the doxycycline-treated patients (p ¼
0.0125) to a level close to that of endemic controls whereas there was no
difference in the placebo group (paired t-test).
DOI: 10.1371/journal.ppat.0020092.g006
Figure 5. Plasma Levels of VEGF-C of Microfilaremic Patients before and
12 Mo after Doxycycline Treatment
Plasma concentrations (mean 6 SD) of VEGF-C were measured from
plasma of microfilaremic patients before and 12 mo after doxycycline
treatment (17 doxycycline treated, 16 placebo, see Table 1). The VEGF-C
levels decreased significantly at 12 mo (preceding supratesticular
lymphatic dilation, see Table 2) in the doxycycline-treated patients (p ¼
0.0198), but no difference in the placebo group occurred (paired t-test).
DOI: 10.1371/journal.ppat.0020092.g005
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the placebo group. A signiﬁcant macroﬁlaricidal effect of
ivermectin and albendazole in placebo patients is, however,
not supported by the USG results, which demonstrated
mostly stable worm nests in placebo patients (conﬁrming
earlier results by Dreyer et al. and others) [47,48], in contrast
to most of the doxycycline-treated patients.
VEGF Levels
Apart from the macroﬁlaricidal effect by doxycycline, the
second observation in this study is that plasma levels of
VEGF-C and its soluble receptor, sVEGFR-3, are signiﬁcantly
elevated in patients infected with ﬁlarial worms, and there is a
correlation between sVEGFR-3 and lymphatic dilation.
Targeting the ﬁlarial worms by doxycycline reduces the levels
of VEGF-C/sVEGFR-3, with amelioration of dilated supra-
testicular lymphatic vessels and improvement in the con-
ditions of lymphedema patients (Table 2, Figure 2). Given that
the sVEGFR-3 are secreted into the plasma following over-
stimulation of the lymphangiogenesis system [59,60], these
data indicate that the stimulation of lymphangiogenesis
followed by lymphatic dilation may be reduced by doxycy-
cline, and the VEGF-C/VEGFR-3 system may constitute a
major mediator of pathological lymphatic dilation. This may
be similar to what pertains in animal models in which
inhibition of the binding of VEGF-C to membrane-bound
VEGFR-3 by sVEGFR-3 led to complete destruction of the
lymphatic network and a lymphedema-like phenotype [36].
Recent studies in solid tumor murine models have also
correlated increased tumor-derived VEGF-C with lymphan-
giogenesis and lymph metastasis [61], supporting a role of
VEGF-C in tumor progression by acting on lymphatic
endothelium. It has also been shown that VEGFR-3 and its
ligand VEGF-C are up-regulated in several diseases such as
AIDS-linked Kaposi’s sarcoma [62] and tumor lymphangio-
genesis in breast cancer [63].
The mean plasma level of VEGF-C given by the manufac-
turer of Quantikine immunoassay enzyme-linked immuno-
sorbent assay (ELISA) kits (R&D Systems, Wiesbaden,
Germany) in a cohort of healthy European individuals is 225
(185–1,231) pg/ml. The levels of endemic normals in the
present study was somewhat higher, with a mean of 1,851 pg/
ml (range 634–2,805); it is not clear whether this reﬂects
genetic differences between people of European descent and
Africans, or a possible exposure of these persons to stimuli of
the lymphangiogenetic system other than lymphatic ﬁlariasis.
However, the levels of VEGF-C in microﬁlaremic and
lymphedema patients were signiﬁcantly increased over those
of endemic normals before treatment. This ﬁnding, and more
so the yet signiﬁcantly elevated levels of sVEGFR-3 in
lymphedema patients in comparison to microﬁlaremic
patients (e.g., those with ﬁlarial infection but without overt
lymphatic pathology), raises the question about the biological
signiﬁcance. Despite a vast literature on VEGF-C or sVEGFR3
expression in tissue (quantitative PCR and immunohistology),
few data on plasma exist for these two factors, which are the
major axis speciﬁc for lymphangiogenesis. What can be
concluded from the available data are the following: (1)
serum levels of VEGF-C are usually 10-fold higher than plasma
levels, because of release from platelets during coagulation;
this also means that plasma levels would be the more reliable
marker since there is no (dominant) interference by platelet-
derived VEGF-C [64]; and (2) measurement of plasma VEGF-C
levels in cancer patients revealed 3-fold higher levels in
comparison to controls [65]. In this regard, it is assumed that
the almost 3-fold increase of plasma VEGF-C levels in our LF
patients over endemic normals would be biologically signiﬁ-
cant based on the comparison with cancer patients. Impor-
tantly, in our study, VEGF-C levels decreased by 12 mo after
doxycycline treatment, well before the supratesticular lym-
phatic dilation improved. The fact that the VEGF-C reduction
preceded the improvement of pathology indicates a possible
causal interaction between lymphangiogenic factors reduced
by doxycycline treatment and lymphatic pathology, rather
than only a coincidence or an epiphenomenon.
A report on VEGF-C levels in cervical cancer patients
provides levels in serum, not plasma, and is therefore not
directly comparable to our data (see the constraints above);
nevertheless, in that report, after anticancer therapy the
levels decreased to the level of controls, accompanied by
concomitant improvement in the conditions of the patients
[66], as also observed in our study in which levels decreased to
those of endemic normals following doxycycline treatment.
Unfortunately no data exist as yet with regard to plasma
sVEGFR3 levels and their biological signiﬁcance for tumors.
However, the more than 3-fold elevation in lymphedema
patients is not considered to be biologically meaningless.
Supratesticular Lymphatic Dilation
The degree of lymphatic dilation caused by ﬁlarial worms is
considered an indirect measurement of the altered lymphatic
function [67]. One study suggests that diffusible secretory
products released either by the adult worm or by the human
Table 3. Primary Variables Measured before and after Treatment in Lymphedema Patients
Treatment Group Time Point after Treatment
Before Treatment 12 mo p-Value
Doxycycline (n ¼ 8) Median of antigenemia (%) (10th–90th percentile) 721 (100%) (200–2,061) 257 (36%) (180–532) 0.1441a
Mean (range) stage of affected legs 3.3 (3–5) 2.3 (2–4) 0.0051b
Mean size of affected legs (cm) 181 178 0.5754b
Placebo (n ¼ 10) Median of antigenemia (%) (10th–90th percentile) 10,807 (100%) (1 271–676 634) 1,145 (11%) (193–337 374) 0.1159a
Mean (range) stage of affected legs 2.5 (2–3) 2.8 (3–4) 0.1088b
Mean circumference of affected legs (cm) 178 175 0.2076b
aChanges in median of antigenemia values before and after treatment were compared by Wilcoxon rank test.
bChanges in the mean stage of affected legs and circumference of affected legs before and after treatment were compared by paired t-test.
DOI: 10.1371/journal.ppat.0020092.t003
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host in response to the parasite may induce lymphatic
dilation [68]. Here, we have provided circumstantial evidence
for both, in a series of events: the lymphatic dilation may be
partly caused by overexpression of VEGF-C/sVEGFR-3 pro-
duced by the endothelial cells of the lymphatic vessels of the
host in response to products of the adult worm that are
reduced by doxycycline. Importantly, the reduction of dilated
vessels was not mechanical as a result of the death of the adult
worms, since the dilated vessels that were analyzed for this
purpose did not contain worm nests.
The mechanism of action of doxycycline on the reduction
of VEGF-C/sVEGFR-3 and its ameliorating effect on lym-
phatic vessel is not yet fully clariﬁed. However, this may be
associated with depletion of Wolbachia from adult ﬁlarial
worms in the lymphatic vessels. There are now valid data
from human studies that Wolbachia stimulate proinﬂamma-
tory cytokines such as TNF, IL-1B, IL-6, and nitric oxide [45],
which are known to up-regulate the expression of VEGF-C;
importantly, these cytokines are down-regulated after dox-
ycycline treatment [45]. This raises the possibility that
proinﬂammatory cytokines such as TNF and IL-1B induced
byWolbachia could affect lymphatic vessels via VEGF-C and its
receptor sVEGFR-3. It is therefore conceivable that any
therapeutic intervention that causes reduction of VEGF-C–
inducing proinﬂammatory cytokines such as TNF, IL-1B [45],
etc. would be able to reduce levels of VEGF-C/sVEGFR-3, and
hence lead to reduction of dilated supratesticular lymphatic
vessels as we have shown here.
In this regard, it is remarkable that there was a signiﬁcant
increase in the prevalence of hydroceles in placebo as
compared to doxycycline treated patients in our study.
Lymphedema Stages
Doxycycline treatment signiﬁcantly reduced the stage of
disease in lymphedema patients, whereas the stage was not
signiﬁcantly altered in placebo patients, who, rather, showed
a trend towards deterioration. The improvement in the stage
in doxycycline patients manifested as better skin texture,
fewer deep folds, and also fewer entry lesions of the affected
legs (unpublished data). This suggests that doxycycline can be
used to improve the clinical manifestations of lymphedema
due to ﬁlariasis. A reduction of the number of adenolym-
phangitis (ADL) attacks that was noted in both, doxycycline
and placebo patients (unpublished data) could be attributed
to the foot-care hygiene training given to all the lymphedema
patients, and with an attempt by patients to demonstrate best
compliance. This is consistent with other reports [8,10,69,70],
which also showed a signiﬁcant reduction of attacks due to
foot-care hygiene. However, a combination of foot-care
hygiene and DEC gave no additional beneﬁts regarding an
improvement of the lymphedema stages [8,69,70]. This
conﬁrms that local limb care is an important intervention,
whereas addition of doxycycline further reduces the severity
of lymphedema. Neither doxycycline nor placebo patients
showed a signiﬁcant reduction of the circumference of the
affected legs. This may be due to the fact that that circum-
ference determination is not a reliable parameter to assess
improvement of the disease, as suggested by Dreyer and co-
workers [47], since it shows considerable variability due to
transient effects such as keeping the leg elevated in the hours
before measurement, or the female monthly hormonal cycle,
etc. [47].
Clinical manifestations of lymphedema do not only hasten
the progression of lymphedema to elephantiasis [71], but also
reduce the workforce and economic resources of the affected
individuals and communities [72,73] in many endemic areas.
Therefore, better treatment options are mandatory.
The current treatment of lymphedema, which mainly relies
on foot hygiene, is suboptimal and still empirical. This is
because it is not clear at present to which extent ADL attacks
are caused by either ﬁlarial worms, including Wolbachia
endosymbionts, by exogenous bacteria, or by both [74,75].
Several chemotherapeutic agents have been tested, but so
far, only 5,6 benzo-alpha-pyrone (coumarin) showed some
encouraging results [76]. However, this drug is no longer
recommended since it has been shown to be hepatotoxic [77].
Penicillin, which acts on some exogenous bacteria such as
Figure 8. Plasma Levels of sVEGFR-3 of Lymphedema Patients before
and 12 Mo after Doxycycline Treatment
Plasma concentrations (mean 6 SD) of sVEGFR-3 were measured from
plasma of lymphedema patients before and 12 mo after doxycycline
treatment. The sVEGFR-3 levels decreased significantly at 12 mo in the
doxycycline-treated patients (p ¼ 0.0251) whereas there was no
difference in the placebo group (paired t-test).
DOI: 10.1371/journal.ppat.0020092.g008
Figure 7. Plasma Levels of VEGF-C of Lymphedema Patients before and
12 Mo after Doxycycline Treatment
Plasma concentrations (mean 6 SD) of VEGF-C were measured from
plasma of lymphedema patients before and 12 mo after doxycycline
treatment. The VEGF-C levels decreased significantly at 12 mo in the
doxycycline-treated patients (p ¼ 0.0499), in contrast to the placebo
group (paired t-test).
DOI: 10.1371/journal.ppat.0020092.g007
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streptococci, but not on Wolbachia endosymbionts, has also
been tested and reported to be beneﬁcial in reducing only the
incidence of ADL attacks [8], but there was no signiﬁcant
reduction in the lymphedema stages [8]. In contrast, in our
study, treatment with doxycycline led to a signiﬁcant
amelioration of lymphedema stages. This could be due to
the fact that doxycycline, in addition to targeting exogenous
bacteria, also targeted Wolbachia endosymbionts and reduced
lymphangiogenic factors along with a reversion of lymph
vessel dilation. In order for doxycycline to exert its
ameliorating activity by targeting Wolbachia, it is mandatory
that the targets, i.e., adult worms or at least incoming L3/4
larvae, are present in the host’s body. Indeed, all our patients
were either CFA-positive (although most they did not exhibit
high levels, as known for lymphedema patients) [78], or they
showed clearly positive antiﬁlarial antibody titers as a sign of
recent exposure (two cases), in accordance with the assump-
tion that it is a characteristic feature of lymphedema that the
patients have a strong immune reaction that is targeted to
incoming L3 and L4 larvae, effectively killing them, however
at the expense of strong inﬂammation [21]. Studies are
currently ongoing to compare the efﬁcacy of doxycycline in
CFA-positive in comparison to a larger group of CFA-
negative lymphedema patients.
Lymphedema patients have a high level of suffering, and it
can be well expected that they would use doxycycline for 6 wk
without the need of a directly observed treatment (DOT).
This is so all the more since the current mass treatment does
not improve lymphedema per se. Hence, doxycycline treat-
ment will have a good chance to be the ﬁrst chemother-
apeutic approach to address lymphatic pathology.
In conclusion, our data are in agreement with the
hypothesis that progression of infection to lymphedema
may be due to overexpression of lymphangiogenic factors
such as VEGF-C and more so, sVEGF-R3, ﬁrst due to the
presence or the death of adult ﬁlarial worms in the lymphatic
vessels and later (in the CFA-negative phase of the disease)
either by the incoming larval stages of the parasite releasing
Wolbachia upon being killed, or (additionally) by skin
commensals such as streptococci [71,79,80] that exacerbate
the condition by stimulating more proinﬂammatory cyto-
kines and VEGF molecules, which are also reduced by
doxycycline. This hypothesis is further supported by another
study [81] in which the level of serum VEGF was shown to
remain the same in patients with bancroftian ﬁlariasis after
DEC treatment [81], which does not have beneﬁcial effects on
lymphedema patients apart from reducing parasite loads [8].
This is probably due to the fact that DEC treatment has no
effect on bacteria (neither Wolbachia nor exogenous species),
and therefore has no effect on proinﬂammatory cytokines
that regulate this VEGF family, although it does partially
reduce adult worm levels.
Although both microﬁlaremic and lymphedema patients
had elevated VEGF-C and sVEGFR-3 levels, those of sVEGFR-
3 were yet signiﬁcantly higher in lymphedema patients
compared to non-lymphedema patients that are micro-
ﬁlaremic (p ¼ 0.0024, Figure 4). This could be an indication
that plasma levels of VEGF-C/sVEGFR-3 may correlate with
disease progression in LF leading to lymphatic dilation and
lymphedema development and hence, might be developed as
prognostic indicators of an increased risk of LF pathology
before it actually becomes manifest. Importantly, reduction
of lymphangiogenic factors preceded the improvement in
pathology. On the one hand, these data argue against a
possible hypothesis that elevated levels of these factors merely
reﬂect infection. On the other, they do offer a potential to
identify individuals who are prone to develop more severe
disease. For this, a prospective study is needed that would
screen VEGF-C and sVEGFR-3 levels in children and young
adults, and monitor development of pathology such as
lymphedema. In human studies of lymphedema families,
heterozygous inactivating missense mutations have been
detected in the tyrosine kinase–encoding region of Flt4
(VEGFR-3) [82], indicating that some lymphedema patients
have dysfunctional lymphatics due to defective VEGFR-3
signaling. This might also be exploited for the development of
an early marker for lymphedema.
Considering the possible effect of VEGF-C/sVEGFR-3 on
lymphatic dilation and lymphedema development, a combi-
nation of classical antiﬁlarial plus antiwolbachial therapy,
which will reduce production of proinﬂammatory cytokines,
may prove to be more effective in treating pathogenesis
associated with LF than antiﬁlarial therapy alone. This study
represents a ﬁrst observation that antiwolbachial therapy
does not only have macroﬁlaricidal activity but may also halt
progression of manifestations associated with lymphatic
ﬁlariasis, and have a potential restorative effect on LF
patients. As discussed earlier, compliance to take doxycycline
for extended periods is not expected to be an issue with
individuals suffering from lymphatic pathology.
Materials and Methods
This placebo-controlled, double-blind study was carried out in the
Nzema East District in the Western region of Ghana. The study was
approved by the Ethical Committee on Human Research and Ethics
of the School of Medical Sciences of Kwame Nkrumah University of
Science and Technology (KNUST), Kumasi, Ghana, as well as by the
ethics committee of the University of Liverpool which acted as a
control body since this work formed part of a European study
network funded by the European Commission. The study conformed
to the principles of the Helsinki Declaration of 1975 (as revised in
1983 and 2000). The trial registration number is ISRCTN 14757.
Study population. Individuals enrolled from the neighboring
villages of Adjan, Domunli, and Akonu in the Western Region of
Ghana took part in the study. No other human ﬁlarial species were
endemic in these villages. A total of 76 (55 males and 21 females)
microﬁlaremic (Figure 1A) and 19 (13 females and six males)
lymphedema (Figure 1B) patients were included in this study. The
study site was selected based on an established occurrence of
lymphatic ﬁlariasis within the surrounding region and clinical
observations (rapid assessment) consistent with symptomatic disease
in a proportion of villagers [44]. Written informed consent was
obtained from all participants. Individuals eligible for participation
were adults of both sexes aged 18–50 y, with a minimum body weight
of more than 40 kg, in good health, and without any clinical condition
requiring chronic medication. Hepatic and renal function and
pregnancy were assessed by dipstick chemistry. Exclusion criteria
encompassed a microﬁlarial load ,50 MF/ml (microﬁlaremic
patients), abnormal hepatic and renal enzymes (aspartate amino-
transferase [AST; 0–40 IU/l], alanine aminotransferase [ALT; 0–45 IU/
l] and creatinine [3–126 lmol/l]), pregnancy, lactation, intolerance to
doxycycline, alcohol or drug abuse, or antiﬁlarial therapy in the last
10 mo.
Randomization of patients and treatment regimens. Random-
ization of patients was carried out using computer-generated random
number software (StatView). Blinding was assured by the exclusion of
persons involved in randomization or tablet packaging in any clinical
or laboratory assessment.
Participants received 2 3 100 mg capsules of doxycycline
(Vibramycin; Pﬁzer, New York, New York, United States) or matching
placebo supplied by the manufacturer daily for a total of 6 wk.
Treatment was done and monitored by a trial clinician in the form of
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daily observed treatment (DOT). Four months after the start of
treatment, all participants received a standard oral dose of 400 mg
albendazole (GlaxoSmithKline, Uxbridge, United Kingdom) and 150–
200 lg/kg ivermectin (Mectizan; Merck, Sharp & Dohme, Clermont-
Ferrand, France).
USG examinations. Male participants were examined using a
portable ultrasound machine (SonoSite 180 Plus; SonoSite, Bothell,
Washington, United States) equipped with a 7.5 MHZ linear trans-
ducer as described previously [83]. Brieﬂy, patients were screened for
worm nests in the scrotal area. Each detected worm nest was
documented using print outs in b-, m-, and pulse-wave Doppler
modes. Additionally, worms in lymphatic vessels were recorded on
DVtapes using a SonyPC 120E Handycam (Sony, Tokyo, Japan)
connected to the ultrasound machine in order to get an animated
documentation of the moving worms. Dilation of the supratesticular
lymphatic vessels containing no worm nests was determined by
measuring the largest diameter using the two-dimensional b-mode.
Since there is no grading system for lymphatic dilation, we developed
a grading system to determine the degree of lymphatic dilation as
follows: category 0 ¼ no dilation (normally up to 0.10 cm [84],
category 1¼ the maximally dilated vessel has a dilation up to 0.20 cm,
category 2 ¼ dilation from 0.21–0.50 cm, category 3 ¼ dilation from
0.51–1.0 cm, and category 4¼ dilation above 1.0 cm (Figure 9A–9D).
The procedure was repeated 12 and 24 mo after treatment.
Determination of microﬁlarial load. For a quick screening in the
night, the microﬁlarial load was determined by microscopic
examination of ﬁnger-prick blood samples as published [44].
Subsequently, eligible patients donated 10 ml of venous blood for
accurate quantiﬁcation using Whatman Nucleopore ﬁlter method as
described previously [44]. The same volume of blood was taken from
each patient 4 and 12 mo after the commencement of doxycycline
treatment, but a lesser volume of 7 ml was taken at 24 mo due to
complaints from the patients. At each time point, plasma was taken
from the remaining sample, aliquoted, and frozen at80 8C for later
analysis of antigenemia and lymphangiogenic factors.
Determination ofWolbachia levels in MF by PCR.Wolbachia content
was quantiﬁed by real-time PCR of the W. bancrofti Wolbachia–ftsZ
gene, derived from 500–1,000 microﬁlariae using a Rotor-Gene 3000
(Corbett Research, Brussels, Belgium) at pretreatment and 4, 12, and
24 mo after treatment. Details of the technique are given in reference
[44]. Brieﬂy, DNA was extracted with DNeasy kit (Qiagen, Hilden,
Germany) following manufacturer’s protocol with Proteinase K
digestion. For the quantiﬁcation, primers and a Taqman hybrid-
ization probe with the ﬂuorescent dye 6-FAM (6-carboxyﬂuorescein)
(Qiagen) were used to amplify a 286-base pair fragment of the W.
bancrofti Wolbachia–ftsZ. The products were quantiﬁed by comparing
with a standard curve of the plasmid containing the W. bancrofti
Wolbachia–ftsZ fragment.
Determination of circulating ﬁlarial antigenemia. For determina-
tion of circulating ﬁlarial antigenemia (ﬁlarial adult worm antigens),
W. bancrofti antigen was measured with the TropBio ELISA test kit
(TropBio, Townsville, Australia). The manufacturer’s protocol was
followed except that the samples were diluted (1:20 ratio) with the
diluent [42] before pipetting into the TropBio ELISA test plates.
Samples were tested in duplicate before treatment and at 12- and 24-
mo follow-ups. The optical density at 414 nm was recorded from
plasma samples. Antigen units were calculated with a standard curve
from standards provided by the manufacturer, and the ﬁnal units
multiplied by the dilution factor of 20.
Limb measurement of lymphedema patients. The circumference of
both affected and normal legs were measured with measuring tape at
ﬁve different points. Measurements were taken at 10 cm from the
large toe, and 12 cm, 20 cm, 30 cm and 50 cm from the sole of the foot
as described in reference [85], and the average of the ﬁve measure-
ments taken as the mean circumference of the leg. Measurements
were taken before and 12 mo post therapy.
Grading or staging of lymphedema legs. Grading or staging of
lymphedema was performed along the guidelines of ‘‘Basic Lymphe-
dema Management’’ [47] (see Figure 10.)
Stage 1 ¼ swelling that is reversible overnight, Stage 2 ¼ swelling
that is not reversible overnight, Stage 3 ¼ shallow skin folds (ankle),
Stage 4 ¼ presence of knobs (lumps or protrusions), Stage 5 ¼ deep
skin folds plus knobs, Stage 6¼ deep skin folds plus knobs and mossy
lesions, and Stage 7 ¼ parameters mentioned above plus patient is
unable to perform routine daily activities.
Foot care and ADL. Before the treatment began, all lymphedema
patients were taught about hygienic care and physical exercises for
the affected legs, and importantly, daily cleansing of affected legs
with soap and water, and keeping the affected leg dry between
washes. All the lymphedema patients were given soap, towels, and
plastic bowls for washing the legs. They were visited every 6 mo in
their villages. At each visit, the patients were asked through a
questionnaire the number of attacks experienced.
Serology test. Filarial antibodies were measured from all the
lymphedema patients before and 12 mo after treatment using the
indirect immunoﬂuorescence antibody (IIFA) test. For antigen
preparation, adult B. malayimales were recovered 6 mo post infection
fromMastomys coucha. Parasites were washed and stored at 4 8C for 4 h.
They were then placed in canine musculature, frozen, and 7-lm
sections were prepared and transferred onto glass slides. Quality was
controlled by using a deﬁned internal control serum (titer 1:320). For
the IIFA test, 100 ll of plasma was inactivated at 56 8C for 30 min, and
diluted 1:10 in PBS (pH 7.2). Seven-fold serial dilutions to 1:1,280
were made from the initial 1:10 screening dilution. A 10-ll volume of
each of the diluted samples was added to separate wells on slides
containing the B. malayi antigens, and incubated at 37 8C in a humid
chamber for 45 min. After the incubation, the IIFA slides were
washed four times for 20 min (33 in 0.1M PBS and 13 in deionized
water). A ﬂuorescein-labeled anti-total human immunoglobulin
(Fluoline-H; bioMerieux, Marcy l’Etoile, France) diluted 1:90 in PBS
was applied to each well and incubated for 45 min at 37 8C in a humid
chamber. The slides were washed four times for 20 min (33 in 0.1M
PBS and 13 in deionized water). Excess water was removed and the
slides dried, covered with glycerol (Euroimmun, Luebeck, Germany),
and cover slides. Wells were observed with a immunoﬂuorescence
microscope (Ernst Leitz, Wetzlar, Germany). Fluorescence of either
the complete worm section including mesenchym and cuticle or only
mesenchym was deﬁned as positive. Fluorescence of the mesenchym
without cuticle was regarded as non-speciﬁc. A titer of nore than 1:80
(including cuticle ﬂuorescence) was regarded as indicative for ﬁlarial
infection. A titer equal to or less than 1:20 was regarded as negative.
Positive and negative controls were included in the test. This test is
validated in regular intervals within a German network of laborato-
ries for quality control.
Determination of plasma levels of VEGF-C and sVEGFR-3. In all
patients, the plasma concentrations of VEGF-C and sVEGFR-3 were
measured using Quantikine immunoassay ELISA kits according to the
manufacturer’s instructions (R&D Systems). After stopping the
reaction, plates were read at 450 nm and 540 nm with a microplate
reader (SPECTRAmax 340PC; Sunnyvale, California, United States).
Twenty-three endemic normals, i.e., residents of the same endemic
area with no evidence of infection conﬁrmed by the lack of
Figure 9. Grading of the Supratesticular Lymphatic Vessel Dilation of
Filarial-Infected Patients Displayed by USG
Dilation of the supratesticular lymphatic vessels was determined by
measuring the largest diameter detectable in the two-dimensional b-
mode of a portable ultrasound machine. A grading system was
developed to determine the degree of lymphatic dilation as follows:
(A) category 1: patients with minimal lymphatic dilation of up to 0.2 cm;
(B) category 2: patients with mild dilation from 0.21–0.50 cm; (C)
category 3: patients with moderate dilation from 0.51–1.0 cm; and (D)
category 4: patients with severe dilation of above 1.0 cm.
DOI: 10.1371/journal.ppat.0020092.g009
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mircoﬁlaraemia and lack of circulating Og4C3 ﬁlarial antigen,
despite exposure to infective larvae borne by mosquitoes, were
included as controls.
Data analysis. Wolbachia loads in worm tissue and microﬁlaremia
were summarized as geometric means (GM). Differences in GM at
baseline and subsequent follow-ups were analyzed using the Wilcoxon
signed rank and Mann-Whitney U tests. Changes in the degree of
antigenemia were calculated as percentages from baseline and
analyzed between treatment groups at subsequent follow-up time
points by the Mann-Whitney U test. Proportions of MF-positive and
MF-negative individuals as well as individuals showing the fFDS
before and after treatment were compared using Fisher’ exact tests.
Plasma levels of the VEGF molecules were expressed as mean 6
standard deviations (SD), and differences in the levels of the VEGF
molecules between endemic normals, microﬁlaremic (MF-positive),
and lymphedema patients were analyzed using analysis of variance
(ANOVA) with the Bonferroni/Dunn post hoc test. Differences in the
levels of the VEGFs within the treatment groups before and 12 mo
after treatment as well as changes in lymphatic vessel dilation, stages
of lymphedema, and the size of affected limbs of lymphedema before
and after treatment were assessed using paired t-tests. Positive
relationships between the disease states and the VEGF molecules
were assessed by the Spearman’ rank correlation test and simple
regression analysis (coefﬁcient of determination indicated as r). A
two-tailed p-value lower than 0.05 was considered signiﬁcant.
Independence of data was tested using multivariate analysis. All
analyses were done using StatView version X for Mac OS 9.5.
Supporting Information
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
bers for the gene and gene products discussed in this paper are:
soluble VEGFR-3 (NM_002020); VEGF-C (CAA63907); andWuchereria
bancrofti Wolbachia–ftsZ gene (AF081198).
Acknowledgments
We thank the individuals of the District Health Management team at
Axim (Nzema East District), Western Region, Ghana, for their
cooperation.
Author contributions. AH, MT, and OA conceived and designed
the experiments. AYD, SM, SS, YMD, LB, KP, and JL performed the
experiments. AYD, SM, BL, and AH analyzed the data. AYD, SM, and
AH wrote the paper.
Funding. We are grateful for ﬁnancial support from the European
Commission (EU grant ICA4-CT-2002–10051) and the VW-Founda-
tion (grant I/7352). Pﬁzer Inc, Karlsruhe, Germany, generously
provided Vibramycin and placebo tablets. AYD is a recipient of
scholarship from the German Academic Exchange Service (DAAD)
for his PhD work.
Competing interests. The authors have declared that no competing
interests exist.
References
1. World Health Organization (2005) WHO annual report on lymphatic
ﬁlariasis 2004. Available: http://www.ﬁlariasis.org. Accessed 12 October
2005.
2. Cox FE (2000) Elimination of lymphatic ﬁlariasis as a public health
problem. Parasitol Today 16: 135.
3. Noroes J, Dreyer G, Santos A, Mendes VG, Medeiros Z, et al. (1997)
Assessment of the efﬁcacy of diethylcarbamazine on adult Wuchereria
bancrofti in vivo. Trans R Soc Trop Med Hyg 91: 78–81.
4. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002)
Mass treatment to eliminate ﬁlariasis in Papua New Guinea. N Engl J Med
347: 1841–1848.
5. Meyrowitsch DW, Simonsen PE, Magesa SM (2004) Long-term effect of
three different strategies for mass diethylcarbamazine administration in
bancroftian ﬁlariasis: Follow-up at 10 years after treatment. Trans R Soc
Trop Med Hyg 98: 627–634.
6. Meyrowitsch DW, Simonsen PE, Makunde WH (1996) Mass DEC chemo-
therapy for control of bancroftian ﬁlariasis: Comparative efﬁcacy of four
strategies two years after start of treatment. Trans R Soc Trop Med Hyg 90:
423–428.
7. Bernhard P, Magnussen P, Lemnge MM (2001) A randomized, double-blind,
placebo-controlled study with diethylcarbamazine for the treatment of
hydrocoele in an area of Tanzania endemic for lymphatic ﬁlariasis. Trans R
Soc Trop Med Hyg 95: 534–536.
8. Joseph A, Mony P, Prasad M, John S, Srikanth, et al. (2004) The efﬁcacies of
affected-limb care with penicillin diethylcarbamazine, the combination of
both drugs or antibiotic ointment, in the prevention of acute adenolym-
phangitis during bancroftian ﬁlariasis. Ann Trop Med Parasitol 98: 685–
696.
9. Freedman DO, Bui T, De Almeida Filho PJ, Braga C, Maia e Silva MC, et al.
(1995) Lymphoscintigraphic assessment of the effect of diethylcarbamazine
treatment on lymphatic damage in human bancroftian ﬁlariasis. Am J Trop
Med Hyg 52: 258–261.
10. Kerketta AS, Babu BV, Rath K, Jangid PK, Nayak AN, et al. (2005) A
randomized clinical trial to compare the efﬁcacy of three treatment
regimens along with footcare in the morbidity management of ﬁlarial
lymphedema. Trop Med Int Health 10: 698–705.
11. Melrose WD (2003) Chemotherapy for lymphatic ﬁlariasis: Progress but not
perfection. Expert Rev Anti Infect Ther 1: 571–577.
12. Das L, Subramanyam Reddy G, Pani S (2003) Some observations on the
effect of Daﬂon (micronized puriﬁed ﬂavonoid fraction of Rutaceae
aurantiae) in bancroftian ﬁlarial lymphedema. Filaria J 2: 5.
13. Addiss DG, Mackenzie C (2004) LF disease—Clinical management. In:
Towards a strategic plan for research to support the global program to
eliminate lymphatic ﬁlariasis. Summary of immediate needs and oppor-
tunities for research on lymphatic ﬁlariasis. Philadelphia, Pennsylvania,
USA, December 9–10, 2003. Am J Trop Med Hyg 71 (Suppl): 12–15.
14. Taylor MJ, Hoerauf A (1999) Wolbachia bacteria of ﬁlarial nematodes.
Parasitol Today 15: 437–442.
15. Saint Andre A, Blackwell NM, Hall LR, Hoerauf A, Brattig NW, et al. (2002)
The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river
blindness. Science 295: 1892–1895.
16. Taylor MJ (2003) Wolbachia in the inﬂammatory pathogenesis of human
ﬁlariasis. Ann N Y Acad Sci 990: 444–449.
17. Hise AG, Gillette-Ferguson I, Pearlman E (2003) Immunopathogenesis of
Onchocerca volvulus keratitis (river blindness): A novel role for TLR4 and
endosymbiotic Wolbachia bacteria. J Endotoxin Res 9: 390–394.
18. Dreyer G, Ottesen EA, Galdino E, Andrade L, Rocha A, et al. (1992) Renal
abnormalities in microﬁlaremic patients with Bancroftian ﬁlariasis. Am J
Trop Med Hyg 46: 745–751.
19. Addiss DG, Dimock KA, Eberhard ML, Lammie PJ (1995) Clinical,
parasitologic, and immunologic observations of patients with hydrocele
and elephantiasis in an area with endemic lymphatic ﬁlariasis. J Infect Dis
171: 755–758.
20. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF (2000) Pathogenesis of
lymphatic disease in bancroftian ﬁlariasis: A clinical perspective. Parasitol
Today 16: 544–548.
21. Ravindran B (2003) Aping Jane Goodall: Insights into human lymphatic
ﬁlariasis. Trends Parasitol 19: 105–109.
22. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K (2004) Lymphatic
vasculature: development, molecular regulation and role in tumor meta-
stasis and inﬂammation. Trends Immunol 25: 387–395.
23. Takahashi M, Yoshimoto T, Kubo H (2004) Molecular mechanisms of
lymphangiogenesis. Int J Hematol 80: 29–34.
24. Witte MH, Bernas MJ, Martin CP, Witte CL (2001) Lymphangiogenesis and
lymphangiodysplasia: From molecular to clinical lymphology. Microsc Res
Tech 55: 122–145.
25. Ruocco V, Schwartz RA, Ruocco E. (2002) Lymphedema: An immunolog-
ically vulnerable site for development of neoplasms. J Am Acad Dermatol
47: 124–127.
26. Saaristo A, Karkkainen MJ, Alitalo K (2002) Insights into the molecular
pathogenesis and targeted treatment of lymphedema. Ann N Y Acad Sci
979: 94–110.
Figure 10. Lymphedema Stages
The lymphedema stages according to the classification by Dreyer et al. [47]; patients are from this study.
(A) Stage 2, swelling that is not reversible overnight.
(B) Stage 3, shallow skin folds at the ankle.
(C) Stage 4, alteration of skin texture and formation of knobs (arrowheads).
(D) Stage 5, presentation of deep skin folds in addition to the alterations of stage 4;
(E) Satge 6, presentation of mossy lesion in addition to the alterations of stage 5.
(F) Stage 7, inability of patient to perform daily work.
DOI: 10.1371/journal.ppat.0020092.g010
PLoS Pathogens | www.plospathogens.org September 2006 | Volume 2 | Issue 9 | e920841
Doxycycline Improves Pathology in LF
27. Korpelainen EI, Alitalo K (1998) Signaling angiogenesis and lymphangio-
genesis. Curr Opin Cell Biol 10: 159–164.
28. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, et al. (1998) Vascular
endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases
VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S
A 95: 548–553.
29. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, et al. (2001)
Signalling via vascular endothelial growth factor receptor-3 is sufﬁcient for
lymphangiogenesis in transgenic mice. EMBO J 20: 1223–1231.
30. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, et al. (1998) Vascular
endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad
Sci U S A 95: 14389–14394.
31. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, et al. (2001) The
speciﬁcity of receptor binding by vascular endothelial growth factor-D is
different in mouse and man. J Biol Chem 276: 19166–19171.
32. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, et al. (1997)
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:
1423–1425.
33. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, et al.
(1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted
to lymphatic endothelium during development. Proc Natl Acad Sci U S A
92: 3566–3570.
34. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, et al. (1996) VEGF-
C receptor binding and pattern of expression with VEGFR-3 suggests a role
in lymphatic vascular development. Development 122: 3829–3837.
35. Taylor MJ, Cross HF, Ford L, Makunde WH, Prasad GB, et al. (2001)
Wolbachia bacteria in ﬁlarial immunity and disease. Parasite Immunol 23:
401–409.
36. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, et al. (2001)
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic
mice expressing soluble VEGF receptor-3. Nat Med 7: 199–205.
37. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K (1998) Proinﬂamma-
tory cytokines regulate expression of the lymphatic endothelial mitogen
vascular endothelial growth factor-C. J Biol Chem 273: 8413–8418.
38. Taylor MJ, Cross HF, Bilo K (2000) Inﬂammatory responses induced by the
ﬁlarial nematode Brugia malayi are mediated by lipopolysaccharide-like
activity from endosymbiotic Wolbachia bacteria. J Exp Med 191: 1429–1436.
39. Raman U, Eswaran D, Narayanan RB, Jayaraman K, Kaliraj P (1999)
Proinﬂammatory cytokines secreted by monocytes of ﬁlarial patients.
Microbiol Immunol 43: 279–283.
40. Brattig NW, Rathjens U, Ernst M, Geisinger F, Renz A, et al. (2000)
Lipopolysaccharide-like molecules derived from Wolbachia endobacteria of
the ﬁlaria Onchocerca volvulus are candidate mediators in the sequence of
inﬂammatory and anti-inﬂammatory responses of human monocytes.
Microbes Infect 2: 1147–1157.
41. Taylor MJ, Bandi C, Hoerauf A (2005) Wolbachia bacterial endosymbionts of
ﬁlarial nematodes. Adv Parasitol 60: 245–284.
42. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, et al. (2005)
Macroﬁlaricidal activity after doxycycline treatment of Wuchereria bancrofti:
A double-blind, randomised placebo-controlled trial. Lancet 365: 2116–
2121.
43. Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, et al.
(2000) Endosymbiotic bacteria in worms as targets for a novel chemo-
therapy in ﬁlariasis. Lancet 355: 1242–1243.
44. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, et al. (2003)
Doxycycline as a novel strategy against bancroftian ﬁlariasis—Depletion of
Wolbachia endosymbionts from Wuchereria bancrofti and stop of microﬁlariae
production. Med Microbiol Immunol 5: 261–273.
45. Turner JD, Mand S, Debrah AY, Muehlfeld J, Pfarr K, et al. (2006) A
randomized, double-blind clinical trial of a 3-week course of doxycycline
plus albendazole and ivermectin for the treatment of Wuchereria bancrofti
infection. Clin Infect Dis 42: 1081–1089.
46. Mand S, Debrah A, Batsa L, Adjei O, Hoerauf A (2004) Reliable and
frequent detection of adult Wuchereria bancrofti in Ghanaian women by
ultrasonography. Trop Med Int Health 9: 1111–1114.
47. Dreyer G, Addiss D, Dreyer P, Noroes J (2002) Basic lymphedema
management: Treatment and prevention of problems associated with
lymphatic ﬁlariasis. Hollis (New Hampshire): Hollis Publishing. 112 p.
48. Bradley MH, Kumaraswami V (2004) Essential tools—Drugs and clinical
drug trials. In: Towards a strategic plan for research to support the global
program to eliminate lymphatic ﬁlariasis. Summary of immediate needs
and opportunities for research on lymphatic ﬁlariasis. Philadelphia,
Pennsylvania, USA, December 9–10, 2003. Am J Trop Med Hyg 71 (Suppl):
7–11.
49. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ (2003) Mass
drug treatment for lymphatic ﬁlariasis and onchocerciasis. Trends Parasitol
19: 516–522.
50. Dadzie Y, Neira M, Hopkins D (2003) Final report of the Conference on the
Eradicability of Onchocerciasis. Filaria J 2: 2.
51. Hoerauf A, Mand S, Volkmann L, Buttner M, Marfo-Debrekyei Y, et al.
(2003) Doxycycline in the treatment of human onchocerciasis: Kinetics of
Wolbachia endobacteria reduction and of inhibition of embryogenesis in
female Onchocerca worms. Microbes Infect 5: 261–273.
52. Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW (2001) Depletion of
Wolbachia endobacteria in Onchocerca volvulus by doxycycline and micro-
ﬁlaridermia after ivermectin treatment. Lancet 357: 1415–1416.
53. Debrah AY, Mand S, Marfo-Debrekyei Y, Larbi J, Adjei O, et al. (2006)
Assessment of microﬁlarial loads in the skin of onchocerciasis patients
after treatment with different regimens of doxycycline plus ivermectin.
Filaria J 5: 1.
54. Lammie PJ (2004) Essential tools—Diagnostics. In: Towards a strategic plan
for research to support the global program to eliminate lymphatic ﬁlariasis.
Summary of immediate needs and opportunities for research on lymphatic
ﬁlariasis. Philadelphia, Pennsylvania, USA, December 9–10, 2003. Am J
Trop Med Hyg 71 (Suppl): 2–5.
55. Dunyo SK, Nkrumah FK, Simonsen PE (2000) A randomized double-blind
placebo-controlled ﬁeld trial of ivermectin and albendazole alone and in
combination for the treatment of lymphatic ﬁlariasis in Ghana. Trans R
Soc Trop Med Hyg 94: 205–211.
56. Simonsen PE, Magesa SM, Dunyo SK, Malecela-Lazaro MN, Michael E
(2004) The effect of single dose ivermectin alone or in combination with
albendazole on Wuchereria bancrofti infection in primary school children in
Tanzania. Trans R Soc Trop Med Hyg 98: 462–472.
57. Critchley J, Addiss D, Ejere H, Gamble C, Garner P, et al. (2005)
Albendazole for the control and elimination of lymphatic ﬁlariasis:
systematic review. Trop Med Int Health 10: 818–825.
58. Ramzy RM, Gad AM, Faris R, Weil GJ (1991) Evaluation of a monoclonal-
antibody based antigen assay for diagnosis of Wuchereria bancrofti infection
in Egypt. Am J Trop Med Hyg 44: 691–695.
59. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, et al. (1996) A
novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4
(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:
1751.
60. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, et al. (1996) Vascular
endothelial growth factor-related protein: a ligand and speciﬁc activator of
the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93: 1988–1992.
61. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, et al. (2001)
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer
metastasis. Nat Med 7: 192–198.
62. Jussila L, Valtola R, Partanen TA, Salven P, Heikkila P, et al. (1998)
Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by
antibodies against the vascular endothelial growth factor receptor-3.
Cancer Res 58: 1599–1604.
63. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. (2001)
Vascular endothelial growth factor-C-mediated lymphangiogenesis pro-
motes tumour metastasis. EMBO J 20: 672–682.
64. Pollitt MJ, Hanby AM, Horgan K, Murphy CE, Jones PF, et al. (2005)
Angiogenesis in breast cancer: how should we measure this? (Review).
Oncol Rep 13: 931–936.
65. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, et al. (2003) Vascular
endothelial growth factors C and D and lymphangiogenesis in gastro-
intestinal tract malignancy. Br J Cancer 89: 426–430.
66. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, et al. (2005) Serum
vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor
markers in patients with cervical carcinoma. Cancer 103: 724–730.
67. Peixoto CA, Figueiredo-Silva J (2001) Fine structure of intrascrotal
lymphatic vessels infected by Wuchereria bancrofti adult worms. J Submicrosc
Cytol Pathol 33: 125–131.
68. Noroes J, Addiss D, Amaral F, Coutinho A, Medeiros Z, et al. (1996)
Occurrence of living adult Wuchereria bancrofti in the scrotal area of men
with microﬁlaremia. Trans R Soc Trop Med Hyg 90: 55–56.
69. Shenoy RK, Suma TK, Rajan K, Kumaraswami V (1998) Prevention of acute
adenolymphangitis in brugian ﬁlariasis: Comparison of the efﬁcacy of
ivermectin and diethylcarbamazine, each combined with local treatment of
the affected limb. Ann Trop Med Parasitol 92: 587–594.
70. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G (1999)
A double-blind, placebo-controlled study of the efﬁcacy of oral penicillin,
diethylcarbamazine or local treatment of the affected limb in preventing
acute adenolymphangitis in lymphedema caused by brugian ﬁlariasis. Ann
Trop Med Parasitol 93: 367–377.
71. Pani SP, Yuvaraj J, Vanamail P, Dhanda V, Michael E, (1995) Episodic
adenolymphagitis and lymphedema in patients with bancroftian ﬁlariasis.
Trans R Soc Trop Med Hyg 89: 72–74
72. Gyapong JO, Gyapong M, Evans DB, Aikins MK, Adjei S (1996) The
economic burden of lymphatic ﬁlariasis in northern Ghana. Ann Trop Med
Parasitol 90: 39–48.
73. Ramaiah KD, Radhamani MP, John KR, Evans DB, Guyatt H, et al. (2000)
The impact of lymphatic ﬁlariasis on labour inputs in southern India:
Results of a multi-site study. Ann Trop Med Parasitol 94: 353–364.
74. Ottesen EA (1993) Filarial infections. Infect Dis Clin North Am 7: 619–633.
75. Addiss DG, Eberhard ML, Lammie PJ (1994) ‘‘Filarial’’ adenolymphangitis
without ﬁlarial infection. Lancet 343: 597.
76. Casley-Smith JR, Jamal S, Casley-Smith J (1993) Reduction of ﬁlaritic
lymphedema and elephantiasis by 5,6 benzo-alpha-pyrone (coumarin), and
the effects of diethylcarbamazine (DEC). Ann Trop Med Parasitol 87: 247–
258.
77. World Health Organization (1996) Coumarin (Lodema). WHO Pharm
Newsl 10: 2.
78. Lalitha P, Ravichandran M, Suba S, Kaliraj P, Narayanan RB, et al. (1998)
PLoS Pathogens | www.plospathogens.org September 2006 | Volume 2 | Issue 9 | e920842
Doxycycline Improves Pathology in LF
Quantitative assessment of circulating antigens in human lymphatic
ﬁlariasis: A ﬁeld evaluation of monoclonal antibody-based ELISA using
blood collected on ﬁlter strips. Trop Med Int Health 3: 41–45.
79. Ewert A, Reitmeyer JC, Folse D (1980) Chronic infection of cats with Brugia
malayiand streptococcus. SoutheastAsian JTropMedPublicHealth11: 32–39.
80. Olszewski WL, Jamal S, Manokaran G, Lukomska B, Kubicka U (1993) Skin
changes in ﬁlarial and non-ﬁlarial lymphedema of the lower extremities.
Trop Med Parasitol 44: 40–44.
81. Esterre P, Plichart C, Huin-Blondey MO, Nguyen LN (2005) Soluble cellular
adhesion molecules, selectins, VEGF and endothelin-1 in patients with
Wuchereria bancrofti infection and association with clinical status. Parasite
Immunol 27: 9–16.
82. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (2000)
Congenital hereditary lymphedema caused by a mutation that inactivates
VEGFR3 tyrosine kinase. Am J Hum Genet 67: 295–301.
83. Mand S, Marfo-Debrekyei Y, Dittrich M, Fischer K, Adjei O, et al. (2003)
Animated documentation of the ﬁlaria dance sign (FDS) in bancroftian
ﬁlariasis. Filaria J 2: 3.
84. Moller R (1980) Arrangement and ﬁne structure of lymphatic vessels in the
human spermatic cord. Adrologia 6: 564–576.
85. Kumaraswami V (2000) The clinical manifestations of lymphatic ﬁlariasis.
In: Nutman TB, editor. Tropical medicine in science and practice. Volume
1. London: Imperial College Press. pp. 103–125
PLoS Pathogens | www.plospathogens.org September 2006 | Volume 2 | Issue 9 | e920843
Doxycycline Improves Pathology in LF
